Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.
Bartelds
G M
GM
Jan van Breemen Institute, Amsterdam, The Netherlands.
Wijbrandts
C A
CA
Nurmohamed
M T
MT
Wolbink
G J
GJ
de Vries
N
N
Tak
P P
PP
Dijkmans
B A C
BA
Crusius
J B A
JB
van der Horst-Bruinsma
I E
IE
D000068879:Adalimumab; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology*; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D004359:Drug Therapy, Combination; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D008727:Methotrexate / Q000276:immunology / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C508609:IL10 protein, human; D016753:Interleukin-10; D000068879:Adalimumab; D008727:Methotrexate